Sunday, September 20, 2026

Aphria Stock Went Up By Over 3% So Far Today

ViaNews Editorial Team

December 23, 2020

Aphria Stock Went Up By Over 3% So Far Today

Shares of Aphria rose 3.65% to $7.38 at 14:38 EST on Wednesday, after two successive sessions in a row of losses. The Nasdaq Stock Market is jumping 0.15% to $12,827.40, following last session's upward trend, This seems, up until now, a somewhat positive trend exchanging session today.

Aphria's last close was $7.12, 20.33% under its 52-week high of $8.88.

Aphria's Stock Yearly Top and Bottom Value

Aphria's stock is valued at $7.38 at 14:38 EST, way under its 52-week high of $8.88 and way higher than its 52-week low of $1.95.

Aphria's Moving Average

Aphria's value is above its 50-day moving average of $6.94 and way higher than its 200-day moving average of $5.27.

Previous days news about Aphria

Aphria, tilray deal is a bet on euro pot: cannabis weekly. According to Bloomberg Quint on Sun Dec 20, "The region is particularly attractive for the hundreds of small Canadian players, who are struggling with an oversupply of raw flower and an uncertain path into the U.S. And the Aphria-Tilray deal could be the first of more Euro-centric transactions.", ""Putting our companies together creates the largest medical cannabis business in Europe, and prepares us if one day legalization happens in the EU," Aphria Chief Executive Officer Irwin Simon told me in a discussion about the deal last week."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com